Post Content
Pfizer Inc. (NYSE:PFE) is one of the
8 Cheap Large Cap Stocks to Buy Now. On April 9, 2026, BofA lowered the price target on Pfizer Inc. (NYSE:PFE) to $26 from $27 and maintained a Neutral rating. BofA said the change reflects updates made as part of its Q1 preview across large-cap pharma and small-to-mid cap biopharma coverage.
On April 1, 2026, a Belgian court ordered Poland and Romania to accept and pay for EUR 1.9B worth of Covid-19 vaccines from Pfizer, rejecting arguments for non-compliance with a European Commission supply contract. Poland is required to take EUR 1.3B worth of doses and Romania EUR 600M after both had refused delivery citing pandemic developments and other concerns.
On March 24, 2026, Guggenheim raised its price target on Pfizer to $36 from $35 and maintained a Buy rating, citing upcoming Phase 3 data for mevrometostat expected in the second half of 2026 and noting potential upside versus downside scenarios tied to the trial outcome.
Photo by National Cancer Institute on Unsplash
On March 23, 2026, Pfizer and Valneva reported Phase 3 VALOR trial results for their Lyme disease vaccine candidate, showing efficacy of 73.2% and 74.8% in two analyses, while noting the first pre-specified statistical criterion was not met due to fewer cases, but indicating plans for regulatory submissions.
Pfizer Inc. (NYSE:PFE) develops and commercializes biopharmaceutical products globally.
While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.